$PALI
PALISADE BIO, INC.

2024 Q1 Form 10-K Financial Statement

#000095017024036402 Filed on March 26, 2024

View on sec.gov

Income Statement

Concept 2024 Q1 2023 Q4 2023
Revenue $0.00 $0.00 $250.0K
YoY Change -100.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.459M $1.558M $6.202M
YoY Change -5.14% 3.52% -29.23%
% of Gross Profit
Research & Development $2.214M $1.733M $6.893M
YoY Change 78.4% -26.03% 5.28%
% of Gross Profit
Depreciation & Amortization $1.000K $4.000K $4.000K
YoY Change 0.0% 100.0% 33.33%
% of Gross Profit
Operating Expenses $3.673M $3.291M $13.32M
YoY Change 32.17% -14.48% -15.27%
Operating Profit -$3.673M -$13.07M
YoY Change 45.24% -16.86%
Interest Expense $1.000K -$4.000K $15.00K
YoY Change -120.0% 15.38%
% of Operating Profit
Other Income/Expense, Net $146.0K $187.0K $770.0K
YoY Change -22.75% 73.15% -47.3%
Pretax Income -$3.527M -$2.971M -$12.30M
YoY Change 50.73% -20.13% -13.74%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$3.527M -$2.971M -$12.30M
YoY Change 50.73% -20.13% -13.74%
Net Earnings / Revenue -4920.0%
Basic Earnings Per Share -$4.59 -$1.80
Diluted Earnings Per Share -$4.59 -$4.81 -$1.80
COMMON SHARES
Basic Shares Outstanding 12.77M 9.217M 6.840M
Diluted Shares Outstanding 768.1K 6.840M

Balance Sheet

Concept 2024 Q1 2023 Q4 2023
SHORT-TERM ASSETS
Cash & Short-Term Investments $11.28M $12.43M $12.43M
YoY Change -15.2% 0.4% 0.4%
Cash & Equivalents $11.30M $12.40M $12.43M
Short-Term Investments
Other Short-Term Assets $584.0K $748.0K $748.0K
YoY Change -14.62% -17.98% -17.98%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $12.01M $13.33M $13.33M
YoY Change -16.05% -9.54% -9.54%
LONG-TERM ASSETS
Property, Plant & Equipment $5.000K $10.00K $208.0K
YoY Change -44.44% 0.0% -32.9%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $438.0K $490.0K $516.0K
YoY Change -31.88% -29.39% -28.33%
Total Long-Term Assets $639.0K $724.0K $724.0K
YoY Change -32.95% -29.71% -29.71%
TOTAL ASSETS
Total Short-Term Assets $12.01M $13.33M $13.33M
Total Long-Term Assets $639.0K $724.0K $724.0K
Total Assets $12.65M $14.05M $14.05M
YoY Change -17.1% -10.85% -10.85%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $459.0K $698.0K $698.0K
YoY Change -34.99% -60.32% -60.32%
Accrued Expenses $1.670M $831.0K $1.730M
YoY Change 440.45% 44.77% 48.5%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $0.00 $158.0K $158.0K
YoY Change 79.55% 79.55%
Total Short-Term Liabilities $2.467M $2.586M $2.586M
YoY Change 87.6% -14.14% -14.14%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $121.0K $153.0K $153.0K
YoY Change -39.5% -43.75% -43.75%
Total Long-Term Liabilities $121.0K $153.0K $153.0K
YoY Change -39.5% -43.75% -43.75%
TOTAL LIABILITIES
Total Short-Term Liabilities $2.467M $2.586M $2.586M
Total Long-Term Liabilities $121.0K $153.0K $153.0K
Total Liabilities $2.588M $2.739M $2.739M
YoY Change 70.83% -16.6% -16.6%
SHAREHOLDERS EQUITY
Retained Earnings -$125.0M $121.5M
YoY Change -212.11% 11.26%
Common Stock $8.000K $93.00K
YoY Change -82.61% 210.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $10.06M $11.31M $11.31M
YoY Change
Total Liabilities & Shareholders Equity $12.65M $14.05M $14.05M
YoY Change -17.1% -10.85% -10.85%

Cashflow Statement

Concept 2024 Q1 2023 Q4 2023
OPERATING ACTIVITIES
Net Income -$3.527M -$2.971M -$12.30M
YoY Change 50.73% -20.13% -13.74%
Depreciation, Depletion And Amortization $1.000K $4.000K $4.000K
YoY Change 0.0% 100.0% 33.33%
Cash From Operating Activities -$3.180M -$2.743M -$11.13M
YoY Change -9.81% -17.03% -16.67%
INVESTING ACTIVITIES
Capital Expenditures $4.000K $4.000K
YoY Change -60.0% -60.0%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$4.000K -$4.000K
YoY Change -60.0% -60.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $9.419M
YoY Change -34.59%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 2.024M -134.0K 11.19M
YoY Change -54.41% -107.82% -26.69%
NET CHANGE
Cash From Operating Activities -3.180M -2.743M -11.13M
Cash From Investing Activities -4.000K -4.000K
Cash From Financing Activities 2.024M -134.0K 11.19M
Net Change In Cash -1.156M -2.881M 49.00K
YoY Change -226.48% 79.84% -97.4%
FREE CASH FLOW
Cash From Operating Activities -$3.180M -$2.743M -$11.13M
Capital Expenditures $4.000K $4.000K
Free Cash Flow -$2.747M -$11.14M
YoY Change -17.16% -16.7%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023 dei Amendment Flag
AmendmentFlag
false
CY2023 dei Entity Central Index Key
EntityCentralIndexKey
0001357459
CY2023 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023 dei Document Type
DocumentType
10-K
CY2023 dei Document Annual Report
DocumentAnnualReport
true
CY2023 dei Document Period End Date
DocumentPeriodEndDate
2023-12-31
CY2023 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2023 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2023 dei Document Transition Report
DocumentTransitionReport
false
CY2023 dei Entity File Number
EntityFileNumber
001-33672
CY2023 dei Entity Registrant Name
EntityRegistrantName
PALISADE BIO, INC.
CY2023 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2023 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
52-2007292
CY2023 dei Entity Address Address Line1
EntityAddressAddressLine1
7750 El Camino Real, Suite 2A
CY2023 dei Entity Address City Or Town
EntityAddressCityOrTown
Carlsbad
CY2023 dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
CY2023 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
92009
CY2023 dei City Area Code
CityAreaCode
858
CY2023 dei Local Phone Number
LocalPhoneNumber
704-4900
CY2023 dei Security12b Title
Security12bTitle
Common Stock, $0.01 par value
CY2023 dei Trading Symbol
TradingSymbol
PALI
CY2023 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2023 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2023 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2023 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2023 dei Entity Small Business
EntitySmallBusiness
true
CY2023 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2023 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
false
CY2023 dei Document Fin Stmt Error Correction Flag
DocumentFinStmtErrorCorrectionFlag
false
CY2023 dei Entity Shell Company
EntityShellCompany
false
CY2023Q2 dei Entity Public Float
EntityPublicFloat
11600000
CY2024Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
12771015
CY2023 dei Auditor Firm
AuditorFirmId
23
CY2023 dei Auditor Name
AuditorName
Baker Tilly US, LLP
CY2023 dei Auditor Location
AuditorLocation
Tewksbury, Massachusetts
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
12432000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
12383000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
896000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2350000
CY2023Q4 us-gaap Assets Current
AssetsCurrent
13328000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
14733000
CY2023Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
26000
CY2022Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
26000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
10000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
10000
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
198000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
300000
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
490000
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
694000
CY2023Q4 us-gaap Assets
Assets
14052000
CY2022Q4 us-gaap Assets
Assets
15763000
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
698000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1759000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
831000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
574000
CY2023Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
778000
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
486000
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
121000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
105000
CY2023Q4 us-gaap Accrued Insurance Current
AccruedInsuranceCurrent
158000
CY2022Q4 us-gaap Accrued Insurance Current
AccruedInsuranceCurrent
88000
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
2586000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
3012000
CY2023Q4 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
2000
CY2022Q4 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
61000
CY2023Q4 us-gaap Business Combination Contingent Consideration Liability Noncurrent
BusinessCombinationContingentConsiderationLiabilityNoncurrent
61000
CY2022Q4 us-gaap Business Combination Contingent Consideration Liability Noncurrent
BusinessCombinationContingentConsiderationLiabilityNoncurrent
0
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
90000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
211000
CY2023Q4 us-gaap Liabilities
Liabilities
2739000
CY2022Q4 us-gaap Liabilities
Liabilities
3284000
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
280000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
280000000
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
9270894
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
9270894
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
2944306
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
2944306
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
93000
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
30000
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
132724000
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
121637000
CY2023Q4 pali Retained Earnings Accumulated Income Deficit
RetainedEarningsAccumulatedIncomeDeficit
-121506000
CY2022Q4 pali Retained Earnings Accumulated Income Deficit
RetainedEarningsAccumulatedIncomeDeficit
-109190000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
11313000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
12479000
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
14052000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
15763000
CY2023 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
250000
CY2022 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
0
CY2023 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
6893000
CY2022 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
6547000
CY2023 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6202000
CY2022 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8764000
CY2023 us-gaap Restructuring Costs
RestructuringCosts
225000
CY2022 us-gaap Restructuring Costs
RestructuringCosts
410000
CY2023 us-gaap Operating Expenses
OperatingExpenses
13320000
CY2022 us-gaap Operating Expenses
OperatingExpenses
15721000
CY2023 us-gaap Operating Income Loss
OperatingIncomeLoss
-13070000
CY2022 us-gaap Operating Income Loss
OperatingIncomeLoss
-15721000
CY2023 us-gaap Interest Expense
InterestExpense
15000
CY2022 us-gaap Interest Expense
InterestExpense
13000
CY2023 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
785000
CY2022 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
2584000
CY2023 pali Financing Cost Derivative Warrant Liabilities
FinancingCostDerivativeWarrantLiabilities
0
CY2022 pali Financing Cost Derivative Warrant Liabilities
FinancingCostDerivativeWarrantLiabilities
1110000
CY2023 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
770000
CY2022 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1461000
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-12300000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-14260000
CY2023 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-12316000
CY2022 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-14548000
CY2023 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
6840213
CY2023 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
6840213
CY2022 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
880311
CY2022 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
880311
CY2023 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.8
CY2023 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.8
CY2022 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-16.53
CY2022 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-16.53
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
12479000
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-12300000
CY2023 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
624000
CY2023 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
17000
CY2023 pali Stock Issued During Period Value Of Common Stock Upon Warrant Exercises
StockIssuedDuringPeriodValueOfCommonStockUponWarrantExercises
1350000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
11313000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
7365000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-14260000
CY2022 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1032000
CY2022 pali Stock Issued During Period Value Of Common Stock Upon Warrant Exercises
StockIssuedDuringPeriodValueOfCommonStockUponWarrantExercises
4956000
CY2022 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
1427000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
12479000
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-12300000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-14260000
CY2023 us-gaap Depreciation
Depreciation
4000
CY2022 us-gaap Depreciation
Depreciation
3000
CY2023 pali Noncash Operating Lease Expense
NoncashOperatingLeaseExpense
102000
CY2022 pali Noncash Operating Lease Expense
NoncashOperatingLeaseExpense
164000
CY2023 pali Issuance Cost Allocated To Warrants
IssuanceCostAllocatedToWarrants
0
CY2022 pali Issuance Cost Allocated To Warrants
IssuanceCostAllocatedToWarrants
1110000
CY2023 us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
204000
CY2022 us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
0
CY2023 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
59000
CY2022 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
2426000
CY2023 us-gaap Share Based Compensation
ShareBasedCompensation
624000
CY2022 us-gaap Share Based Compensation
ShareBasedCompensation
1032000
CY2023 us-gaap Increase Decrease In Other Operating Capital Net
IncreaseDecreaseInOtherOperatingCapitalNet
108000
CY2022 us-gaap Increase Decrease In Other Operating Capital Net
IncreaseDecreaseInOtherOperatingCapitalNet
233000
CY2023 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-705000
CY2022 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-1027000
CY2023 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-492000
CY2022 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
399000
CY2023 us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
292000
CY2022 us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-25000
CY2023 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-105000
CY2022 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-151000
CY2023 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-11133000
CY2022 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-13360000
CY2023 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
4000
CY2022 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
10000
CY2023 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-4000
CY2022 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-10000
CY2023 us-gaap Repayments Of Short Term Debt
RepaymentsOfShortTermDebt
391000
CY2022 us-gaap Repayments Of Short Term Debt
RepaymentsOfShortTermDebt
790000
CY2023 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
9419000
CY2022 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
14401000
CY2023 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
2758000
CY2022 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
2274000
CY2023 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
617000
CY2022 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
627000
CY2023 us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
17000
CY2022 us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
0
CY2023 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
11186000
CY2022 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
15258000
CY2023 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
49000
CY2022 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
1888000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
12409000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
10521000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
12458000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
12409000
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
12432000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
12383000
CY2023Q4 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
26000
CY2022Q4 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
26000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
12458000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
12409000
CY2023 us-gaap Interest Paid Net
InterestPaidNet
14000
CY2022 us-gaap Interest Paid Net
InterestPaidNet
12000
CY2023 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
0
CY2022 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
355000
CY2023 pali Equity Issuance Costs Included In Accounts Payable
EquityIssuanceCostsIncludedInAccountsPayable
0
CY2022 pali Equity Issuance Costs Included In Accounts Payable
EquityIssuanceCostsIncludedInAccountsPayable
388000
CY2023 pali Non Cash Impact Of Exercise Price Reset On Outstanding Warrants Related To Down Round Provisions
NonCashImpactOfExercisePriceResetOnOutstandingWarrantsRelatedToDownRoundProvisions
16000
CY2022 pali Non Cash Impact Of Exercise Price Reset On Outstanding Warrants Related To Down Round Provisions
NonCashImpactOfExercisePriceResetOnOutstandingWarrantsRelatedToDownRoundProvisions
288000
CY2023 pali Issuance Of Common Stock For Cashless Exercise Of Warrants
IssuanceOfCommonStockForCashlessExerciseOfWarrants
0
CY2022 pali Issuance Of Common Stock For Cashless Exercise Of Warrants
IssuanceOfCommonStockForCashlessExerciseOfWarrants
1274000
CY2023 pali Fair Value Of Warrants Issued To Placement Agent
FairValueOfWarrantsIssuedToPlacementAgent
384000
CY2022 pali Fair Value Of Warrants Issued To Placement Agent
FairValueOfWarrantsIssuedToPlacementAgent
55000
CY2023 pali Fair Value Of Warrants Issued To Underwriter Agent
FairValueOfWarrantsIssuedToUnderwriterAgent
0
CY2022 pali Fair Value Of Warrants Issued To Underwriter Agent
FairValueOfWarrantsIssuedToUnderwriterAgent
459000
CY2023 pali Deferred Equity Issuance Costs Recognized As A Reduction In Additional Paid In Capital From Financing Activities
DeferredEquityIssuanceCostsRecognizedAsAReductionInAdditionalPaidInCapitalFromFinancingActivities
6000
CY2022 pali Deferred Equity Issuance Costs Recognized As A Reduction In Additional Paid In Capital From Financing Activities
DeferredEquityIssuanceCostsRecognizedAsAReductionInAdditionalPaidInCapitalFromFinancingActivities
0
CY2023 pali Cash Receivable For Exercises Of Warrants Included In Prepaid And Other Assets And Other Noncurrent Assets
CashReceivableForExercisesOfWarrantsIncludedInPrepaidAndOtherAssetsAndOtherNoncurrentAssets
0
CY2022 pali Cash Receivable For Exercises Of Warrants Included In Prepaid And Other Assets And Other Noncurrent Assets
CashReceivableForExercisesOfWarrantsIncludedInPrepaidAndOtherAssetsAndOtherNoncurrentAssets
1408000
CY2023 us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
0
CY2022 us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
1000
CY2023 pali Net Proceeds From Insurance Financing Debt Included In Prepaid And Other Assets And Oher Noncurrent Assets
NetProceedsFromInsuranceFinancingDebtIncludedInPrepaidAndOtherAssetsAndOherNoncurrentAssets
461000
CY2022 pali Net Proceeds From Insurance Financing Debt Included In Prepaid And Other Assets And Oher Noncurrent Assets
NetProceedsFromInsuranceFinancingDebtIncludedInPrepaidAndOtherAssetsAndOherNoncurrentAssets
784000
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
121500000
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
12400000
CY2023 us-gaap Use Of Estimates
UseOfEstimates
<p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of Estimates</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">preparation of financial statements in conformity with U.S. GAAP requires the Company to make estimates, judgments, and assumptions that impact the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities as of the date of the balance sheet, and the reported amounts of expenses during the reporting period. The most significant estimates in the Company’s consolidated financial statements relate to pre-clinical and clinical trial accruals, contingent consideration liabilities, and its derivative financial instruments. Although these estimates are based on the Company’s knowledge of current events and actions it may undertake in the future, actual results may materially differ from these estimates and assumptions.</span></p>
CY2023 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2023 us-gaap Number Of Reportable Segments
NumberOfReportableSegments
1
CY2023Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
26000
CY2022Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
26000
CY2023Q4 us-gaap Deferred Costs Current
DeferredCostsCurrent
112000
CY2022Q4 us-gaap Deferred Costs Current
DeferredCostsCurrent
114000
CY2023 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Concentration of Credit Risk</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Financial instruments, which potentially subject the Company to concentration of credit risk, consist primarily of cash and cash equivalents. The Company maintains deposits in federally insured financial institutions and in money market accounts, and at times balances may exceed federally insured limits. Management believes that the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held and historically the Company has not experienced any losses in such accounts.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
CY2023 us-gaap Revenue Recognition Software
RevenueRecognitionSoftware
<p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">License Revenue</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company uses the revenue recognition guidance established by ASC 606, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Revenue From Contracts With Customers</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> (“ASC 606”). When an agreement falls under the scope of other standards, such as ASC 808, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Collaborative Arrangements</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, the Company will apply the recognition, measurement, presentation, and disclosure guidance in ASC 606 to the performance obligations in the agreements if those performance obligations are with a customer. The Company currently does not have any collaborative arrangements with counterparties that are also considered customers. For arrangements that include amounts to be paid to the Company upon the achievement of certain development milestones of technology licensed by the Company, the Company recognizes such license revenue using the most likely method. At the end of each reporting period, the Company re-evaluates the probability or achievement of any potential milestones and any related constraints, and if necessary, adjusts its estimates of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenue in the period of adjustment.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-12300000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-14260000
CY2023 us-gaap Warrant Down Round Feature Increase Decrease In Equity Amount1
WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1
-16000
CY2022 us-gaap Warrant Down Round Feature Increase Decrease In Equity Amount1
WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1
-288000
CY2023 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-12316000
CY2023 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-12316000
CY2022 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-14548000
CY2022 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-14548000
CY2023 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
6840213
CY2023 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
6840213
CY2022 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
880311
CY2022 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
880311
CY2023 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.8
CY2023 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.8
CY2022 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-16.53
CY2022 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-16.53
CY2023 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5171601
CY2022 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1099459
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
490000
CY2023 us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Reclassifications</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Certain prior year amounts have been reclassified to conform to the current year presentation. During the fourth quarter of 2023, the Company reclassified the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">fair value of the contingent consideration milestone payment obligation associated with the Giiant License Agreement, including transaction related costs, from In-process research and development expenses to Research and development expenses at the consolidated statement of operations, which impacted amounts previously reported for the three and nine months ended September 30, 2023. Amounts reported for the year ended December 31, 2022 were not impacted by this reclassification.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
CY2023Q4 us-gaap Prepaid Insurance
PrepaidInsurance
428000
CY2022Q4 us-gaap Prepaid Insurance
PrepaidInsurance
581000
CY2023Q4 pali Prepaid Expenses And Other Current Assets Other Receivables
PrepaidExpensesAndOtherCurrentAssetsOtherReceivables
148000
CY2022Q4 pali Prepaid Expenses And Other Current Assets Other Receivables
PrepaidExpensesAndOtherCurrentAssetsOtherReceivables
1438000
CY2023Q4 pali Prepaid Subscriptions And Fees
PrepaidSubscriptionsAndFees
138000
CY2022Q4 pali Prepaid Subscriptions And Fees
PrepaidSubscriptionsAndFees
157000
CY2023Q4 pali Prepaid Software Licenses
PrepaidSoftwareLicenses
64000
CY2022Q4 pali Prepaid Software Licenses
PrepaidSoftwareLicenses
54000
CY2023Q4 us-gaap Deferred Finance Costs Current Net
DeferredFinanceCostsCurrentNet
112000
CY2022Q4 us-gaap Deferred Finance Costs Current Net
DeferredFinanceCostsCurrentNet
114000
CY2023Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
6000
CY2022Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
6000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
896000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2350000
CY2022 pali Cash Receivable For Exercises Of Warrants Included In Prepaid And Other Assets And Other Noncurrent Assets
CashReceivableForExercisesOfWarrantsIncludedInPrepaidAndOtherAssetsAndOtherNoncurrentAssets
1400000
CY2023Q4 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
0
CY2023Q4 us-gaap Prepaid Expense Noncurrent
PrepaidExpenseNoncurrent
478000
CY2022Q4 us-gaap Prepaid Expense Noncurrent
PrepaidExpenseNoncurrent
682000
CY2023Q4 pali Other Noncurrent Assets
OtherNoncurrentAssets
12000
CY2022Q4 pali Other Noncurrent Assets
OtherNoncurrentAssets
12000
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
694000
CY2023Q4 pali Accrued Accounts Payable
AccruedAccountsPayable
166000
CY2022Q4 pali Accrued Accounts Payable
AccruedAccountsPayable
69000
CY2023Q4 pali Accrued Clinical Trial Costs
AccruedClinicalTrialCosts
20000
CY2022Q4 pali Accrued Clinical Trial Costs
AccruedClinicalTrialCosts
184000
CY2023Q4 pali Accrued Director Stipends
AccruedDirectorStipends
106000
CY2022Q4 pali Accrued Director Stipends
AccruedDirectorStipends
141000
CY2023Q4 us-gaap Supplemental Unemployment Benefits Severance Benefits
SupplementalUnemploymentBenefitsSeveranceBenefits
131000
CY2022Q4 us-gaap Supplemental Unemployment Benefits Severance Benefits
SupplementalUnemploymentBenefitsSeveranceBenefits
180000
CY2023Q4 pali Accrued Joint Development Expenses
AccruedJointDevelopmentExpenses
98000
CY2022Q4 pali Accrued Joint Development Expenses
AccruedJointDevelopmentExpenses
0
CY2023Q4 us-gaap Business Combination Contingent Consideration Liability Current
BusinessCombinationContingentConsiderationLiabilityCurrent
143000
CY2022Q4 us-gaap Business Combination Contingent Consideration Liability Current
BusinessCombinationContingentConsiderationLiabilityCurrent
0
CY2023Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
167000
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
0
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
831000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
574000
CY2023Q4 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
4080876
CY2022Q4 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
1055672
CY2023Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
205201
CY2023Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
0.84
CY2022Q4 pali Class Of Warrant Or Right Number Outstanding
ClassOfWarrantOrRightNumberOutstanding
1055672
CY2022 pali Class Of Warrant Or Right Outstanding Weighted Average Exercise Price
ClassOfWarrantOrRightOutstandingWeightedAverageExercisePrice
26.48
CY2022 pali Class Of Warrant Or Right Outstanding Weighted Average Remaining Contractual Life
ClassOfWarrantOrRightOutstandingWeightedAverageRemainingContractualLife
P3Y3M25D
CY2023 pali Class Of Warrant Or Right Issued During Period
ClassOfWarrantOrRightIssuedDuringPeriod
5302192
CY2023 pali Class Of Warrant Or Right Issued During Period Weighted Average Exercise Price
ClassOfWarrantOrRightIssuedDuringPeriodWeightedAverageExercisePrice
1.75
CY2023 pali Class Of Warrant Or Right Issued During Period Weighted Average Remaining Contractual Life
ClassOfWarrantOrRightIssuedDuringPeriodWeightedAverageRemainingContractualLife
P4Y7M20D
CY2023 pali Class Of Warrant Or Right Exercised During Period
ClassOfWarrantOrRightExercisedDuringPeriod
2203993
CY2023 pali Class Of Warrant Or Right Exercised During Period Weighted Average Exercise Price
ClassOfWarrantOrRightExercisedDuringPeriodWeightedAverageExercisePrice
0.61
CY2023 pali Class Of Warrant Or Right Exercised During Period Weighted Average Remaining Contractual Life
ClassOfWarrantOrRightExercisedDuringPeriodWeightedAverageRemainingContractualLife
P0Y8M23D
CY2023 pali Class Of Warrant Or Right Forfeited Expired Or Cancelled During Period
ClassOfWarrantOrRightForfeitedExpiredOrCancelledDuringPeriod
72995
CY2023 pali Class Of Warrant Or Right Forfeited Expired Or Cancelled During Period Weighted Average Exercise Price
ClassOfWarrantOrRightForfeitedExpiredOrCancelledDuringPeriodWeightedAverageExercisePrice
4.86
CY2023Q4 pali Class Of Warrant Or Right Number Outstanding
ClassOfWarrantOrRightNumberOutstanding
4080876
CY2023 pali Class Of Warrant Or Right Outstanding Weighted Average Exercise Price
ClassOfWarrantOrRightOutstandingWeightedAverageExercisePrice
8.63
CY2023 pali Class Of Warrant Or Right Outstanding Weighted Average Remaining Contractual Life
ClassOfWarrantOrRightOutstandingWeightedAverageRemainingContractualLife
P4Y1M13D
CY2023Q3 us-gaap Business Combination Contingent Consideration Liability Noncurrent
BusinessCombinationContingentConsiderationLiabilityNoncurrent
200000
CY2023Q4 us-gaap Business Combination Contingent Consideration Liability Noncurrent
BusinessCombinationContingentConsiderationLiabilityNoncurrent
61000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
280000000
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2023 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
1.39
CY2022 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
40.32
CY2023 pali Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Expected Term
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedTerm
P5Y7M28D
CY2022 pali Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Expected Term
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedTerm
P5Y9M21D
CY2023 pali Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageRiskFreeInterestRate
0.0408
CY2022 pali Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageRiskFreeInterestRate
0.023
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Expected Dividend
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend
0
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Expected Dividend
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend
0
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
0.7835
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
0.7366
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
43658
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
311.74
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y29D
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
0
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
669180
CY2023 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
1.39
CY2023 pali Share Based Compensation Arrangement By Share Based Payment Award Options Granted Weighted Average Remaining Contractualterm2
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualterm2
P9Y6M25D
CY2023 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
0
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
47366
CY2023 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
57.98
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
665472
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
17.6
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P9Y4M13D
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
1000
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
665472
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
17.6
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P9Y4M13D
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
1000
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
97981
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
108.57
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P8Y2M4D
CY2023Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
0
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
0.82
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
26.15
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Vested
SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested
300000
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Vested
SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested
1000000
CY2023 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
606000
CY2022 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1032000
CY2023Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
600000
CY2023 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P1Y9M18D
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Outstanding Weighted Average Remaining Contractual Terms
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms
P2Y29D
CY2023Q4 pali Accrued Joint Development Expenses
AccruedJointDevelopmentExpenses
98000
CY2018 pali Collaborations And License Agreements Upfront Fee
CollaborationsAndLicenseAgreementsUpfrontFee
1000000
CY2018 us-gaap Royalty Expense
RoyaltyExpense
6750000
CY2023 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
300000
CY2023Q4 pali Class Of Warrant Or Right Number Of Rights Issued
ClassOfWarrantOrRightNumberOfRightsIssued
1
CY2023 pali Contingent Value Right Pro Rata Net Proceeds From Sale Or Licensing
ContingentValueRightProRataNetProceedsFromSaleOrLicensing
0.80
us-gaap Royalty Expense
RoyaltyExpense
4500000
pali Maximum Aggregate Consideration
MaximumAggregateConsideration
5000000
pali Milestone Payments
MilestonePayments
1500000
pali Closing Period Of Merger Agreement
ClosingPeriodOfMergerAgreement
P48M
pali Proceeds Deposited Into The Cvr Escrow
ProceedsDepositedIntoTheCvrEscrow
0.20
pali Closing Period Of Merger Agreement
ClosingPeriodOfMergerAgreement
P48M
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
136000
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
93000
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
229000
CY2023Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
18000
CY2023Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
211000
CY2022Q4 us-gaap Restructuring Reserve
RestructuringReserve
180000
CY2021Q4 us-gaap Restructuring Reserve
RestructuringReserve
0
CY2023 us-gaap Restructuring Reserve Accrual Adjustment1
RestructuringReserveAccrualAdjustment1
225000
CY2022 us-gaap Restructuring Reserve Accrual Adjustment1
RestructuringReserveAccrualAdjustment1
410000
CY2023 us-gaap Payments For Restructuring
PaymentsForRestructuring
274000
CY2022 us-gaap Payments For Restructuring
PaymentsForRestructuring
230000
CY2023Q4 us-gaap Restructuring Reserve
RestructuringReserve
131000
CY2022Q4 us-gaap Restructuring Reserve
RestructuringReserve
180000
CY2023 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-2583000
CY2022 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-2995000
CY2023 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
-810000
CY2022 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
-1040000
CY2023 us-gaap Income Tax Reconciliation Nondeductible Expense Meals And Entertainment
IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment
3000
CY2022 us-gaap Income Tax Reconciliation Nondeductible Expense Meals And Entertainment
IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment
0
CY2023 pali Income Tax Reconciliation Nondeductible Expense Warrants
IncomeTaxReconciliationNondeductibleExpenseWarrants
-12000
CY2022 pali Income Tax Reconciliation Nondeductible Expense Warrants
IncomeTaxReconciliationNondeductibleExpenseWarrants
-276000
CY2023 us-gaap Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost
IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
522000
CY2022 us-gaap Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost
IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
60000
CY2023 pali Income Tax Reconciliation Other Non Deductible Expenses
IncomeTaxReconciliationOtherNonDeductibleExpenses
-89000
CY2022 pali Income Tax Reconciliation Other Non Deductible Expenses
IncomeTaxReconciliationOtherNonDeductibleExpenses
71000
CY2023 pali Income Tax Reconciliation Nondeductible Expense Expiration Of Tax Attributes
IncomeTaxReconciliationNondeductibleExpenseExpirationOfTaxAttributes
484000
CY2022 pali Income Tax Reconciliation Nondeductible Expense Expiration Of Tax Attributes
IncomeTaxReconciliationNondeductibleExpenseExpirationOfTaxAttributes
484000
CY2023 us-gaap Income Tax Reconciliation Change In Enacted Tax Rate
IncomeTaxReconciliationChangeInEnactedTaxRate
207000
CY2022 us-gaap Income Tax Reconciliation Change In Enacted Tax Rate
IncomeTaxReconciliationChangeInEnactedTaxRate
-157000
CY2023 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
2278000
CY2022 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
3853000
CY2023 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2022 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2023Q4 pali Deferred Tax Assets Accrued Expenses
DeferredTaxAssetsAccruedExpenses
128000
CY2022Q4 pali Deferred Tax Assets Accrued Expenses
DeferredTaxAssetsAccruedExpenses
91000
CY2023Q4 pali Deferred Tax Assets Depreciation
DeferredTaxAssetsDepreciation
245000
CY2022Q4 pali Deferred Tax Assets Depreciation
DeferredTaxAssetsDepreciation
192000
CY2023Q4 pali Deferred Tax Assets Lease Accounting
DeferredTaxAssetsLeaseAccounting
55000
CY2022Q4 pali Deferred Tax Assets Lease Accounting
DeferredTaxAssetsLeaseAccounting
87000
CY2023Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
24703000
CY2022Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
22681000
CY2023Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
1470000
CY2022Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
1955000
CY2023Q4 us-gaap Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
2515000
CY2022Q4 us-gaap Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
1912000
CY2023Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
29116000
CY2022Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
26918000
CY2023Q4 pali Deferred Tax Liabilities Right Of Use Asset
DeferredTaxLiabilitiesRightOfUseAsset
52000
CY2022Q4 pali Deferred Tax Liabilities Right Of Use Asset
DeferredTaxLiabilitiesRightOfUseAsset
83000
CY2023Q4 us-gaap Deferred Tax Liabilities Prepaid Expenses
DeferredTaxLiabilitiesPrepaidExpenses
112000
CY2022Q4 us-gaap Deferred Tax Liabilities Prepaid Expenses
DeferredTaxLiabilitiesPrepaidExpenses
160000
CY2023Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
164000
CY2022Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
243000
CY2023Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
28952000
CY2022Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
26675000
CY2023Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
28952000
CY2022Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
26675000
CY2023Q4 us-gaap Deferred Tax Liabilities
DeferredTaxLiabilities
0
CY2022Q4 us-gaap Deferred Tax Liabilities
DeferredTaxLiabilities
0
CY2022 pali Uncertain Income Tax Positions
UncertainIncomeTaxPositions
0
CY2023 pali Uncertain Income Tax Positions
UncertainIncomeTaxPositions
0

Files In Submission

Name View Source Status
R23.htm Edgar Link pending
0000950170-24-036402-index-headers.html Edgar Link pending
0000950170-24-036402-index.html Edgar Link pending
0000950170-24-036402.txt Edgar Link pending
0000950170-24-036402-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
img60995965_0.jpg Edgar Link pending
img60995965_1.jpg Edgar Link pending
img60995965_2.jpg Edgar Link pending
img60995965_3.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
pali-20231231.htm Edgar Link pending
pali-20231231.xsd Edgar Link pending
pali-ex23_1.htm Edgar Link pending
pali-ex31_1.htm Edgar Link pending
pali-ex31_2.htm Edgar Link pending
pali-ex32_1.htm Edgar Link pending
pali-ex97_1.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
pali-20231231_htm.xml Edgar Link completed
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending